Efficacy of methylergometrine during the early puerperium: a randomized double-blind placebo-controlled clinical trial by Sparice, S et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ijmf20
The Journal of Maternal-Fetal & Neonatal Medicine
ISSN: 1476-7058 (Print) 1476-4954 (Online) Journal homepage: http://www.tandfonline.com/loi/ijmf20
Efficacy of methylergometrine during the early
puerperium: a randomized double-blind placebo-
controlled clinical trial
Stefania Sparice, Pierluigi Giampaolino, Anna Sansone, Gabriele Saccone,
Vincenzo Berghella & Costantino Di Carlo
To cite this article: Stefania Sparice, Pierluigi Giampaolino, Anna Sansone, Gabriele Saccone,
Vincenzo Berghella & Costantino Di Carlo (2018): Efficacy of methylergometrine during the early
puerperium: a randomized double-blind placebo-controlled clinical trial, The Journal of Maternal-
Fetal & Neonatal Medicine, DOI: 10.1080/14767058.2018.1529750
To link to this article:  https://doi.org/10.1080/14767058.2018.1529750
Accepted author version posted online: 27
Sep 2018.
Published online: 29 Oct 2018.




Efficacy of methylergometrine during the early puerperium: a randomized
double-blind placebo-controlled clinical trial
Stefania Sparicea, Pierluigi Giampaolinoa, Anna Sansonea, Gabriele Sacconeb , Vincenzo Berghellac and
Costantino Di Carlod
aDepartment of Public Health, School of Medicine, University of Naples “Federico II”, Naples, Italy; bDepartment of Neuroscience,
Reproductive Sciences and Dentistry, School of Medicine, University of Naples “Federico II”, Naples, Italy; cDivision of Maternal-Fetal
Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia,
PA, USA; dDepartment of Clinical and Experimental Medicine, University of Catanzaro “Magna Graecia”, Catanzaro, Italy
ABSTRACT
Objective: To determine if oral methylergometrine administration during the first 10 d following
spontaneous vaginal delivery has any beneficial effect on the increase of hemoglobin levels.
Methods: This was a parallel group double-blind placebo-controlled clinical trial conducted at
single center university hospital in Italy. Participants were puerperal women, who delivered
singleton gestation with spontaneous vaginal delivery at term. Participants were randomized
into a 1:1 ratio to receive either 0.125mg methylergometrine per os twice a day or placebo for
10 d. Hemoglobin levels were recorded on the day of delivery and after 10 d. The primary out-
come was the variation in hemoglobin levels between the first and the 10th day of treatment.
Results: From December 2012 to October 2015, 220 agreed to take part in the study, under-
went randomization, and were enrolled and followed-up. Of the randomized women, 110 (50%)
were randomized to the methylergometrine group and 110 (50%) to the placebo group. No
women were excluded after randomization or lost to follow-up (100%). We found no significant
difference in the median variation of hemoglobin levels between the intervention and the pla-
cebo group
Conclusions: The use of 10 d oral methylergometrine in puerperal women was not associated
with any benefit in the variation of hemoglobin levels from delivery to 10 d after delivery.
KEY MESSAGE
Methylergometrine in puerperal women was not associated with any benefit.
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Methylergometrine is an ergot derivative belonging to
the group of oxytocic drugs, which enhance uterine
motility. Parenteral administration of these agents dur-
ing the third stage of labor has been shown to be
effective in reducing the maternal blood loss [1]. In
this setting, the use of methylergometrine or oxytocin
leads to comparable effects [1].
Only few studies have investigated the routine use of
prophylactic methylergometrine during the puerperium
for reducing bleeding during the postnatal period
[2–10]. A Cochrane meta-analysis reported that “there
was insufficient evidence to support the use of prophy-
lactic oral methylergometrine given after delivery” [7],
concluding that large, well-designed, placebo-controlled
randomized clinical trials are warranted.
Thus, the hypothesis of this trial was that in puer-
peral women the use of 10-days prophylactic oral
methilergometrine would reduce bleeding during the
postnatal period.
Materials and methods
Study design and participants
This was a single-center parallel group randomized
clinical trial of puerperal women, who delivered single-
ton gestation with spontaneous vaginal delivery at
term, and who were randomized to receive either
methylergometrine or placebo at University of Naples
“Federico II” (Naples, Italy) from December 2012 to
October 2015.
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The trial was approved by the local ethics commit-
tee (Prot. No. 75/10 approved on 23.06.2010). All partic-
ipants in the trial provided written informed consent.
Inclusion criteria were 18–50 years of age, spontan-
eous vaginal delivery at term, singleton gestations, low
risk pregnancy, fetal weight between 2800 and 3800 g,
hemoglobin levels the day of the delivery >10g/dL.
Exclusion criteria were: high-risk pregnancy (e.g.
hypertension disorder, cardiovascular disease, IUGR), pre-
term delivery, operative delivery, prior cesarean delivery,
history of postpartum hemorrhage in a prior pregnancy,
retained placenta at delivery, severe perineal trauma
(either third- or fourth-degree laceration) at delivery,
episiotomy at the time of delivery, unknown or
10g/dL hemoglobin levels the day of the delivery,
established postpartum hemorrhage (i.e. blood loss
>500mL) at the time of delivery.
Eligible women were those who delivered singleton
gestation at term with spontaneous vaginal delivery.
Consented women were randomized soon after the
delivery. All randomized women received a complete
blood count 2 h and 10 d after delivery. All included
women received active management of the third
stage of labor, as per our protocol. Active manage-
ment of the third stage of labor included prophylactic
oxytocin and controlled cord traction, as these
interventions have been proven to be effective and
are considered standard of care [11–14].
Randomized women received either 0.125mg meth-
ylergometrine per os twice a day for 10 d starting 12 h
after delivery, or placebo. The capsules were identical
regarding color, shape, size, and packing. The methyl-
ergometrine were manufactured by Novartis Farma
SpA. The placebo was prepared by Pierrel Research
IMP, Cantu, Italy.
Randomization and masking
Eligible participants were randomly allocated in a 1:1
ratio to either methylergometrine or placebo. Women
were randomized by a web-based system. The ran-
domization sequence was prepared by an independ-
ent statistician. Clinicians did not have advance access
to the randomization sequence. Participants, outcome
assessors, data collectors, and data analysts were
blinded to the allocated treatment group. Assessment
of the outcomes and outcome collection were made
by clinicians not involved in the clinical trial and
reported in a form with only the trial ID as identifier.
The data analyst was blind until the entire analysis
was completed.
Management of the enrolled women
A complete blood count was performed 2 h and 10 d
after delivery. A total of 5mL blood was collected in
EDTA VacutainerVR Tubes from each patient. All
specimens were processed using an Automated
Hematology Analyzer (Advia 2120i, Siemens
Healthcare, Berlin, Germany) within 30min of the
blood being drawn. A transabdominal ultrasound with
calculation of uterine volume was performed 1 d and
10 d after delivery. All the ultrasound scans were per-
formed on a Voluson 730 Expert machine using a con-
vex probe RealTime 4D and a 4–8MHz transducer (GE
Healthcare, Chalfont St Giles, United Kingdom). The
uterus was assessed in the transverse and the sagittal
plane and its volume was calculated according to the
ellipse formula [(length transverse diameter fundal
anteroposterior diameter)/3 0.5233].
Outcomes
The primary outcome was the variation in hemoglobin
levels between the first and the 10th day of treatment.
The prespecified secondary outcomes were the vari-
ation in uterine volume between the first and the 10th
day of treatment, and the incidence of postpartum endo-
metritis. Endometritis was defined as temperature greater
than 37.5 C with one or more symptoms or signs: uter-
ine tenderness, maternal tachycardia greater than 100
bpm, purulent or foul-smelling cervical discharge or
maternal leukocytosis greater than 12,000 cells/mL3.
Sample size calculation
The calculation of the sample size was based on the
following considerations: in the 10 d following a spon-
taneous vaginal delivery, hemoglobin level shows usu-
ally an increase of approximately 1.5 g/dL with a SD of
±3, in comparison with immediate postpartum values.
From a clinical point of view, we would consider
useful a treatment that allows an increase of hemoglo-
bin 1.5 g/dL greater than placebo.
We determined that a sample size of 220 (110 per
group) patients would provide a power of 80% with a
two-sided type 1 error of 5%.
Statistical analysis
Data are shown as means, or as number (percentage).
Univariate comparisons of dichotomous data were per-
formed with the use of the Chi-square test with con-
tinuity correction. Comparisons between groups were
performed with the use of the T-test to test group
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means by assuming equal within-group variances. The
primary analysis was an intention to treat comparison
of the treatment assigned at randomization. A two-
sided p value less than .05 was considered significant.
Statistical analysis was performed using statistical
package for social sciences (SPSS, Chicago, IL) v. 19.0
(IBM Inc., Armonk, NY).
Results
From December 2012 to October 2015, 220 women
agreed to take part in the study, underwent random-
ization, and were enrolled and followed-up (Figure 1).
Of the randomized women, 110 (50%) were random-
ized to the methylergometrine group and 110 (50%)
to the placebo group. No women were excluded after
randomization or lost to follow-up (100%).
Table 1 shows the baseline demographic and
clinical characteristics for each group. The two groups
were similar in terms of maternal demographics.
After 10 d, no significant differences were found in
the variation in the hemoglobin level or in the vari-
ation of the uterine volume between the two groups
(Table 2). No cases of endometritis were reported in
either group.
Discussion
This randomized double-blind placebo-controlled clin-
ical trial showed that use of 10-d prophylactic oral
methylergometrine in puerperal women was not asso-
ciated with any benefit in the variation of hemoglobin
levels from delivery to 10 d after delivery. Strengths of
the study included the use of placebo as control, the
study design, and the blinding of participants and per-
sonnel. We achieved exactly our trial registry planned
sample size of 220 women, with no over, or under-
recruitment, 100% follow-up and 100% compliance
with treatment allocation in both groups.
Few studies have been performed on the use of
methylergometrine during puerperium. Klug et al. [4].
and Arabin et al. [2] did not found any benefit in the
prophylactic oral use of methylergometrine in the early
puerperium. They also found that this intervention was
associated with an increased incidence of severe uter-
ine cramps, endometritis, and pelvic pain [2]. Iatrakis
et al. [5] compared single dose versus multiple doses of
methylergometrine after delivery, finding a reduction in
the rate of endometritis in the intervention group. Our
trial concurred with the prior literature and provided
evidences that prophylactic oral use of methylergome-
trine in the early puerperium was not associated with
Figure 1. Study flow chart.
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any benefits. Notably, ergot derivatives may also induce
coronary spasm [8,10,15]. Serious ischemic cardiac
events related to these drugs are rare and have most
often been described after intravenous use. However,
recently, at least two cases of myocardial infarction
after oral administration of methylergometrine have
been reported [8,10]. Therefore, a judicious use of ergot
alkaloids seems mandatory.
Conclusions
In conclusion, the use of 10-d prophylactic oral meth-
ylergometrine in puerperal women was not associated
with any benefit in the variation of hemoglobin levels.
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